source
- Gilead pushes further into immunology, touts inflammation drug pipelineGilead Sciences’ senior leadership has repeatedly emphasized the company’s long‑term ambition to expand beyond its virology roots into the inflammatory and autoimmune space. The messaging, delivere…
- Novartis and Novo Nordisk trials lower biomarkers but fail to cut heart events, prompting preventive cardiology rethinkThe article discusses two recent Phase 3 trials that achieved their biological goals but did not improve clinical outcomes. Novartis reported that pelacarsen in the Lp(a) HORIZON study successfull…